Articolo di Review(s)
30 giugno 2019
V. 7 (2019)
Lo screening del tumore del polmone: una revisione di letteratura
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
349
Visite
220
Downloads
Autori
Obiettivi: Analisi critica della letteratura sul problema dello screening del tumore del polmone e sintesi tra evidenza scientifica ed applicabilità nella pratica clinica. Metodologia: selezione ed esame degli studi maggiormente rilevanti anche per potenza statistica. Risultati: discussione di tre studi positivi con maggiore numerosità del campione (NLST, NELSON e MILD) e dei loro limiti e criticità. Conclusioni: a fronte di risultati senz’altro significativi e stimolanti, emerge una sostanziale difficoltà di implementazione nella pratica clinica, per costi, necessità di elevato expertise e training di personale dedicato, teorica migliore allocazione di risorse nei programmi di disassuefazione da fumo, possibile futura disponibilità di metodiche biomolecolari integrabili nei programmi per un migliore risultato.
Altmetrics
Downloads
La data di download non è ancora disponibile.
Citations
AIOM/AIRTUM, I numeri del cancro in Italia, Ed. Intermedia, 2018. https://www.aiom.it/wp-content/uploads/2018/10/2018_NumeriCancro-operatori.pdf
Black WC, Gareen IF, Soneji SS, Sicks JD, Keeler EB, Aberle DR, Naeim A, Church TR, Silvestri GA, Gorelick J, Gatsonis C; National Lung Screening Trial Research Team. “Cost-effectiveness of CT screening in the National Lung Screening Trial”. NEJM Nov 6;371(19):1793-802, 2014. DOI: https://doi.org/10.1056/NEJMoa1312547
De Koning HJ, WCLC 2018, Abs. PL02.05
Doria-Rose VP, Szabo E. “Screening and prevention of lung cancer”. In: Kernstine KH, Reckamp KL, eds. Lung cancer: a multidisciplinary approach to diagnosis and management. New York: Demos Medical Publishing, 2010:53-72.
Gaëlle Coureau, L. Rachid Salmi, Cécile Etard, Hélène Sancho-Garnier, Catherine Sauvaget, Simone Mathoulin-Pélissier, “Low-dose computed tomography screening for lung cancer in populations highly exposed to tobacco: A systematic methodological appraisal of published randomised controlled trials”, European Journal of Cancer 61, 146-156, 2016. DOI: https://doi.org/10.1016/j.ejca.2016.04.006
Hasan N, Kumar R, Kavuru MS. “Lung cancer screening beyond low-dose computed tomography: the role of novel biomarkers”. Lung 2014;192:639–48. DOI: https://doi.org/10.1007/s00408-014-9636-z
Horeweg N, Scholten ET, de Jong PA, van der Aalst CM, Weenink C, Lammers JW, Nackaerts K, Vliegenthart R, ten Haaf K, Yousaf-Khan UA, Huevelmans MA, Thunnissen E, Oudkerk M, Mali W, de Koning HJ, “Detection of Lung Cancer through low-dose CT screening (NELSON): a prespeciefied analysis of screening test performance and interval cancers” Lancet Oncol Nov; 15(12): 1342-50, 2014. DOI: https://doi.org/10.1016/S1470-2045(14)70387-0
IASLC, World Conference on Lung Cancer, 2018
Langevin SM, Kratzke RA, Kelsey KT. “Epigenetics of lung cancer. Translational research”. J Lab Clin Med 2015;165:74–90.
Naidich DP, Marshall CH, Gribbin C, Arams RS, McCauley DI. “Low-dose CT of the lungs: preliminary observations”. Radiology;175:729-31, 1990.
Matthijs Oudkerk, Anand Devaraj, Rozemarijn Vliegenthart, Thomas Henzler, Helmut Prosch, Claus P Heussel, Gorka Bastarrika, Nicola Sverzellati, Mario Mascalchi, Stefan Delorme, David R Baldwin, Matthew E Callister, Nikolaus Becker, Marjolein A Heuvelmans, Witold Rzyman, Maurizio V Infante, Ugo Pastorino, Jesper HPedersen, Eugenio Paci, Stephen W Duffy, Harry de Koning, John K Fiel “European position statement on lung cancer screening”, Lancet Oncol; 18: e754-66, 2017. DOI: https://doi.org/10.1016/S1470-2045(17)30861-6
Paci E, “The narrow path to organized LDCT lung cancer screening programs in Europe”, J Thorac Dis; 10 (7): 4556-4564, 2018. DOI: https://doi.org/10.21037/jtd.2018.07.08
Pastorino U, Silva M, Sestini S, Sabia F, Boeri M, Cantarutti A, Sverzellati N, Sozzi G, Corrao G, Marchianò A, “Prolonged lung cancer screening reduced 10-year mortality in the MILD trial: new confirmation of lung cancer screening efficacy”, Annals of Oncology 0: 1–8, 2019. DOI: https://doi.org/10.1093/annonc/mdz169
Richard Peto, Sarah Darby, Harz Deo, Paul Silcocks, Elise Whitley, Richard Doll, “Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case - control studies”, BMJ, vol 321, 5 Aug 2000. DOI: https://doi.org/10.1136/bmj.321.7257.323
Pinsky PF, Church TR, Izmirlian G, Kramer BS, “The National Lung Screening Trial: results stratified by demographics, smoking history, and lung cancer histology”, Cancer, Nov 15;119(22):3976-83, 2013. DOI: https://doi.org/10.1002/cncr.28326
Rai A, Doria-Rose VP, Silvestri GA, Yabroff KR, “Evaluating Lung cancer Screening Uptake, Outcomes, and Costs in the United States: Challenges With Existing Data and Recommendations for Improvement”, J Natl Cancer Inst. Apr 1; 111(4): 342-349, 2019. DOI: https://doi.org/10.1093/jnci/djy228
Silvestri GA, Vachani A, Whitney D, et al. “A bronchial genomic classifier for the diagnostic evaluation of lung cancer”. N Engl J Med 2015;373:243–51. DOI: https://doi.org/10.1056/NEJMoa1504601
Surgeon General Report, US Dept. Health and Human Services, 2014.
The National Lung Screening Trial Research Team. “The National Lung Screening Trial: overview and study design”. Radiology 2011;258:243-53. DOI: https://doi.org/10.1148/radiol.10091808
The National Lung Screening Trial Research Team. “Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening”. NEJM, vol. 35 no. 5, 2011.
Yousaf-Khan U, van der Aalst C, de Jong PA, Huevelmans M, Scholten E, Lammers JW, van Ooijen P, Nackaerts K,Weenink C, Groen H, Vliegenthart R, Ten Haaf K, Oudkerk M, de Koning H, “Final screening round of the NELSON lung cancer screening trial: the effect of a 2.5-year screening interval”, Thorax, Jan;72(1): 48-76, 2017. DOI: https://doi.org/10.1136/thoraxjnl-2016-208655
Come citare
Lo screening del tumore del polmone: una revisione di letteratura. (2019). Working Paper of Public Health, 7(1). https://doi.org/10.4081/wpph.2019.9211
